Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles.


Journal

ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991

Informations de publication

Date de publication:
25 Nov 2020
Historique:
pubmed: 11 11 2020
medline: 26 2 2021
entrez: 10 11 2020
Statut: ppublish

Résumé

Tumor-associated macrophages (TAMs), a major player in the tumor microenvironment, were recently recognized as a potential therapeutic target. To date, very few anticancer drugs or drug-delivery systems were designed to target the TAMs. Inspired by the "eat me" signal, phosphatidylserine (PS), mediated phagocytic clearance of apoptotic bodies, in this study, the matrix metalloproteinase 2 (MMP2)-sensitive PS-modified nanoparticles were developed. In the design, the PS is externalized to the nanoparticles' surface only when the nanoparticles reach the MMP2-overexpressing tumor site, allowing for the TAM-specific phagocytosis. The nanoparticles' excellent macrophage/TAM selectivity was observed in various biological models, including various cell lines, coculture cells, coculture cell spheroids, zebrafish, and tumor-bearing mice. The nanoparticles' TAM specificity remarkably enhanced the TAM depletion capability of the loaded model drug, dasatinib, resulting in the improved anticancer activity. The MMP2-sensitive apoptotic body-mimicking nanoparticles might be a promising delivery tool for TAM-centered cancer diagnoses and treatments.

Identifiants

pubmed: 33169982
doi: 10.1021/acsami.0c15983
pmc: PMC8229024
mid: NIHMS1714507
doi:

Substances chimiques

Antineoplastic Agents 0
Phosphatidylserines 0
Polyethylene Glycols 3WJQ0SDW1A
Matrix Metalloproteinase 2 EC 3.4.24.24
Dasatinib RBZ1571X5H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52402-52414

Subventions

Organisme : NCI NIH HHS
ID : R15 CA213103
Pays : United States

Références

ACS Nano. 2012 Apr 24;6(4):3491-8
pubmed: 22409425
Nat Rev Drug Discov. 2014 Dec;13(12):904-27
pubmed: 25376097
J Biol Chem. 1993 Feb 15;268(5):3530-7
pubmed: 8429029
Cancer Res. 2015 Oct 1;75(19):4063-73
pubmed: 26238785
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Methods Mol Biol. 2008;440:15-33
pubmed: 18369934
Int J Oncol. 2000 Oct;17(4):673-81
pubmed: 10995877
J Control Release. 2014 Jun 10;183:114-23
pubmed: 24698945
Br J Pharmacol. 2007 Jul;151(6):844-50
pubmed: 17533418
Cancer Immunol Res. 2017 Feb;5(2):157-169
pubmed: 28073775
J Immunol. 2003 May 1;170(9):4840-5
pubmed: 12707367
Biomaterials. 2011 May;32(13):3435-46
pubmed: 21295849
Nanomedicine. 2019 Jul;19:71-80
pubmed: 31004812
J Cell Biol. 2001 Nov 12;155(4):649-59
pubmed: 11706053
Chem Commun (Camb). 2019 Apr 4;55(29):4254-4257
pubmed: 30901007
J Control Release. 2015 Aug 28;212:94-102
pubmed: 26113423
Free Radic Biol Med. 2007 Apr 1;42(7):945-54
pubmed: 17349923
Clin Cancer Res. 2001 Aug;7(8):2396-404
pubmed: 11489818
Trends Pharmacol Sci. 2018 Aug;39(8):766-781
pubmed: 30032745
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Nat Rev Drug Discov. 2005 Jan;4(1):35-44
pubmed: 15688071
Pathol Res Pract. 2011 Dec 15;207(12):747-53
pubmed: 22030137
Curr Biol. 2006 Nov 7;16(21):2156-60
pubmed: 17084701
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):475-9
pubmed: 1302560
J Clin Invest. 2006 Aug;116(8):2132-2141
pubmed: 16862213
J Biomed Nanotechnol. 2016 Jun;12(6):1199-210
pubmed: 27319214
Cell Rep. 2016 May 31;15(9):2000-11
pubmed: 27210762
Am J Pathol. 1993 Nov;143(5):1406-15
pubmed: 8238256
ACS Appl Mater Interfaces. 2017 Oct 25;9(42):36642-36654
pubmed: 28960955
Nature. 1974 Aug 23;250(5468):667-9
pubmed: 4546859
ACS Appl Mater Interfaces. 2017 Nov 22;9(46):39971-39984
pubmed: 29076344
Nano Today. 2015 Aug;10(4):487-510
pubmed: 26640510
Cancer Lett. 2004 Aug 10;211(2):235-42
pubmed: 15219947
Eur J Cancer. 2003 Sep;39(13):1948-56
pubmed: 12932675
Cancer Cell. 2011 Jan 18;19(1):31-44
pubmed: 21215706
Mol Ther. 2005 Sep;12(3):468-74
pubmed: 15963763
Cell Biochem Biophys. 2014 Jan;68(1):143-52
pubmed: 23812723
J Immunol. 2004 Dec 1;173(11):6973-80
pubmed: 15557194
Int J Cancer. 2006 Sep 15;119(6):1403-11
pubmed: 16615109
ACS Appl Mater Interfaces. 2016 May 25;8(20):12661-73
pubmed: 27145021
J Immunol Methods. 1995 Jul 17;184(1):39-51
pubmed: 7622868
Cell. 1996 May 31;85(5):683-93
pubmed: 8646777
Biochim Biophys Acta. 2010 Jan;1803(1):103-20
pubmed: 19800930
J Biol Chem. 1995 Jul 21;270(29):17250-6
pubmed: 7615524
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Clin Cancer Res. 2011 Sep 15;17(18):6061-70
pubmed: 21810917
Oncotarget. 2017 Jun 27;8(26):41827-41840
pubmed: 28611279
Biomaterials. 2015 Oct;67:104-14
pubmed: 26210177
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17047-52
pubmed: 24062440
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Br J Cancer. 2006 Aug 7;95(3):272-81
pubmed: 16832418
ACS Nano. 2014 Jul 22;8(7):7014-26
pubmed: 24945994
Blood. 2012 Nov 29;120(23):4533-43
pubmed: 22936666
Leukemia. 2009 Mar;23(3):590-4
pubmed: 18784745
J Lipid Res. 2009 Nov;50(11):2157-63
pubmed: 19017616
ACS Appl Mater Interfaces. 2017 Sep 27;9(38):32520-32533
pubmed: 28870072
Br J Pharmacol. 2008 Aug;154(7):1400-13
pubmed: 18552866

Auteurs

Yin Liu (Y)

Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University College Station, Kingsville 78363, Texas, United States.

Jiao Wang (J)

Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University College Station, Kingsville 78363, Texas, United States.

Jian Zhang (J)

Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University College Station, Kingsville 78363, Texas, United States.

Sandra Marbach (S)

Department of Life Sciences, College of Science and Engineering, Texas A&M University, Corpus Christi 78412, Texas, United States.

Wei Xu (W)

Department of Life Sciences, College of Science and Engineering, Texas A&M University, Corpus Christi 78412, Texas, United States.

Lin Zhu (L)

Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University College Station, Kingsville 78363, Texas, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH